Home > Products > B cell lymphoma BCL1 Idiotype & CD3 > Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scDiabody-CH3)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scDiabody-CH3)  (CAT#: SCDBC-016)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scDiabody-CH3) is a fusion protein of two scDiabodies connected together by a CH3 region. In single-chain Diabodies, an additional connecting linker is introduced between chains of the anti-B cell lymphoma BCL1 Idiotype/anti-CD3 diabody. The scDiabody with two specificities is fused to each of the CH3 chains to extend half-life. This BsAb can block cell adhesion. It is designed for the research of B cell lymphoma therapy.
Datasheet INQUIRY

Specifications

Targets
B cell lymphoma BCL1 Idiotype & CD3
Type
scDiabody-CH3
Species Reactivity
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
B cell lymphoma
Host Animal 1
Rat
Host Animal 2
Mouse

Targets

Target 1
B cell lymphoma BCL1 Idiotype
Alternative Names
B cell lymphoma BCL1 Idiotype; B cell lymphoma; BCL1; Idiotype; Id; 31D1; 32D1
Target 2
CD3
Gene ID
UniProt ID
Alternative Names
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3; AI504783
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

See other bsAb targets related to "CD3"

See other bsAb targets related to "B cell lymphoma BCL1 Idiotype"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scDiabody-CH3) (SCDBC-016). Click the button below to contact us or submit your feedback about this product.